Publications
24
Citations
53
Est. group size
—
Recurring co-author estimate
Active years
17
Publishing since 2009
Typically publishes in teams of ~13 · 0% small-team papers (≤3 authors) · across 2 venues
- Paradigm Change in COPD Management: The Critical Role of Medical Education to Enhance Adoption of Biologic for COPD With Eosinophilic Phenotype
American Journal of Respiratory and Critical Care Medicine · 2025
- Association of Small Airway Disease and Progression to COPD
American Journal of Respiratory and Critical Care Medicine · 2025
- Dupilumab Improves Lung Function in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation: A Pooled Analysis from the Phase 3 NOTUS and BOREAS Trials
American Journal of Respiratory and Critical Care Medicine · 2025
- Cardiopulmonary Risk Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate Triple Therapy: A Number Needed to Treat Post Hoc Analysis of the ETHOS Trial
American Journal of Respiratory and Critical Care Medicine · 2025
- The Size and Location Features of Mucus Plugs in COPD Differ Depending on the Extent of Emphysema
American Journal of Respiratory and Critical Care Medicine · 2025
- Assessment of Disease Stability in Patients With COPD Receiving Single-Inhaler Therapy With Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI: Post Hoc Analysis of the IMPACT Trial
American Journal of Respiratory and Critical Care Medicine · 2025
- Safety and Efficacy of Budesonide-Glycopyrrolate-Formoterol Fumarate for COPD in Black or African-American Patients: A Post-Hoc Subgroup Analysis of the ETHOS Study
2021
- InforMing the PAthway of COPD Treatment (étude IMPACT) : triple thérapie en un inhalateur unique (Furoate de Fluticasone/Umeclidinium/Vilanterol) comparée à Furoate de Fluticasone/Vilanterol et Umeclidinium/Vilanterol chez les patients atteints de bronchopneumopathie chronique obstructive (BPCO) : analyse basée sur les traitements de la BPCO à l’inclusion
Revue des Maladies Respiratoires Actualités · 2020
- Preventing Clinically Important Deterioration (CID) of COPD with Single-inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol: A Prospective Analysis of the IMPACT Trial
2019
- The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: A Pre-Specified Analysis of Safety According to Age
2019
- The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Rescue Use and Night-Time Awakenings
2019
- The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Cardiovascular Safety
2019
- Hemoglobin as a Biomarker for Clinical Outcomes in Chronic Obstructive Pulmonary Disease
2019
- The IMPACT Trial: Single Inhaler Triple Therapy fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Analysis According to Smoking Status
2019
- American Journal of Respiratory and Critical Care Medicine×9
- Revue des Maladies Respiratoires Actualités×1
- Meilan Han
Medicine · University of Michigan
- Roy A. Pleasants
Medicine · University of Michigan
- Catherine A. Meldrum
Medicine · University of Michigan
- M.H. Cho
Medicine · Purdue University West Lafayette
- MeiLan K. Han
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile